Acquired Hemophilia A Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Novo Nordisk, Sanofi, Pfizer, Belief BioMed, Centessa Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acquired Hemophilia A pipeline constitutes 10+ key companies continuously working towards developing 10+ Acquired Hemophilia A treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Acquired Hemophilia A Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/acquired-hemophilia-a-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acquired Hemophilia A Market.

The Acquired Hemophilia A Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Acquired Hemophilia A Pipeline Report

*
Companies across the globe are diligently working toward developing novel Acquired Hemophilia A treatment therapies with a considerable amount of success over the years. Acquired Hemophilia A Key players such as - Belief Biomed, ISU ABXIS, TiumBio, Be Biopharma, Regeneron Pharmaceuticals, Pfizer, Biocad, CSL Behring, Shanghai Vitalgen BioPharma, Baxalta, Amarna therapeutics, Catalyst Biosciences, Freeline Therapeutics, Belief BioMed, Centessa Pharmaceuticals, Novo Nordisk, Sanofi, Pfizer, and others are developing therapies for the Acquired Hemophilia A treatment

*
Acquired Hemophilia A Emerging therapies such as - BBM-H901, ISU304, TU7710, BE-101, REGV131, PF-06838435, ANB-002, AAV5-hFIXco-Padua, VGB-R04, AskBio009, AMA005, CB 2679d-GT, FLT180a, BBM-H901, SerpinPC, Concizumab, Fitusiran, PF-06, and others are expected to have a significant impact on the Acquired Hemophilia A market in the coming years.

*
In September 2025, Novo Nordisk has filed an application with the U.S. Food and Drug Administration for approval to market Mim8 (denecimig), an injectable therapy aimed at preventing bleeding in individuals with hemophilia A, with or without inhibitors. If approved, Mim8 would be available as a single-use, prefilled disposable pen for subcutaneous injections, administered on a weekly, biweekly, or monthly schedule.

*
In June 2025, According to a study published in Leukemia titled "Anti-CD19 CAR-T cell therapy for acquired hemophilia A," CAR T-cell therapy-an immune-based treatment initially developed for cancer-has, for the first time, been successfully used to treat a patient with acquired hemophilia A (AHA). Hemophilia A is characterized by a deficiency or dysfunction of factor VIII (FVIII), a key clotting protein. This deficiency increases the risk of severe and prolonged bleeding episodes. The condition arises from genetic mutations affecting the gene responsible for producing FVIII.

*
In February 2025, Researchers have documented two cases where factor VIII inhibitors were successfully eliminated in patients with acquired hemophilia A treated with rituximab. Published in Hematology, these reports highlighted rituximab as both safe and effective, potentially serving as a first-line therapy for acquired hemophilia A. The authors explained, "Rituximab, a monoclonal antibody targeting CD20-positive B cells, shows promise in treating acquired hemophilia by decreasing the production of autoantibodies against factor VIII." They also noted that current guidelines recommend rituximab as a first-line option primarily for patients with poor prognosis or those who cannot tolerate standard first-line treatments.

*
In July 2024, Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced Pfizer Inc.'s positive topline results from the Phase 3 AFFINE trial (NCT04370054). The study evaluates giroctocogene fitelparvovec, an investigational gene therapy co-developed by Sangamo and licensed to Pfizer for treating adults with moderately severe to severe hemophilia A.

*
In May 2024, Danish pharmaceutical firm Novo Nordisk announced key findings from FRONTIER II, a Phase IIIa study evaluating subcutaneous Mim8 for haemophilia A treatment.

Acquired Hemophilia A Overview

Acquired Hemophilia A is a rare autoimmune bleeding disorder in which the body produces antibodies (autoantibodies) that attack clotting factor VIII, a protein essential for blood clotting. Unlike congenital hemophilia, it develops later in life and is not inherited. This condition can lead to spontaneous, severe bleeding into the skin, muscles, or internal organs, even in individuals with no prior history of bleeding disorders. It is often associated with other conditions such as autoimmune diseases, cancer, or pregnancy, but can also occur without a known cause. Prompt diagnosis and treatment are essential to manage bleeding and control the immune response.

To know more about the Acquired Hemophilia A pipeline report, click here:

https://www.delveinsight.com/report-store/acquired-hemophilia-a-pipeline-insight [https://www.delveinsight.com/report-store/acquired-hemophilia-a-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Acquired Hemophilia A Pipeline Therapies along with Key Players:

*
BBM-H901: Belief Biomed

*
ISU304: ISU ABXIS

*
TU7710: TiumBio

*
BE-101: Be Biopharma

*
REGV131: Regeneron Pharmaceuticals

*
PF-06838435: Pfizer

*
ANB-002: Biocad

*
AAV5-hFIXco-Padua: CSL Behring

*
VGB-R04: Shanghai Vitalgen BioPharma

*
AskBio009: Baxalta

*
AMA005: Amarna therapeutics

*
CB 2679d-GT: Catalyst Biosciences

*
FLT180a: Freeline Therapeutics

*
BBM-H901: Belief BioMed

*
SerpinPC: Centessa Pharmaceuticals

*
Concizumab: Novo Nordisk

*
Fitusiran: Sanofi

*
PF-06741086: Pfizer

Acquired Hemophilia A Pipeline Therapeutics Assessment

TheAcquired Hemophilia A Pipeline report proffers an integral view of the Acquired Hemophilia A emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

Acquired Hemophilia A Pipeline Clinical Phases:

DelveInsight's Report covers around 10+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I) along with the details of

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Further Acquired Hemophilia A product details are provided in the report. Download the Acquired Hemophilia A pipeline report to learn more about the emerging Acquired Hemophilia A therapies [https://www.delveinsight.com/sample-request/acquired-hemophilia-a-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Acquired Hemophilia A Therapeutics Market include:

Key companies developing therapies for Acquired Hemophilia A treatment are - Aptevo, Bayer, BioMarin, Catalyst Biosciences, CSL Behring, GC Pharma, Kaifeng Pharmaceutical, KM Biologics, LFB, Novo Nordisk, Pfizer, Octapharma, Roche, Sanofi, SinoCelltech, Spark Therapeutics, Takeda, UniQure, and others.

Acquired Hemophilia A Pipeline Analysis:

The report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the Acquired Hemophilia A treatment with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acquired Hemophilia A Treatment.

*
Acquired Hemophilia A key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Acquired Hemophilia A Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acquired Hemophilia A market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Acquired Hemophilia A Pipeline Market Drivers

*
Increasing prevalence of Acquired Hemophilia A disease

*
Increasing R&D on identifying new therapeutic agents

Acquired Hemophilia A Pipeline Market Barriers

*
High cost of Acquired Hemophilia A treatment

Scope of Acquired Hemophilia A Pipeline Drug Insight

*
Coverage: Global

*
Key Acquired Hemophilia A Companies: Belief Biomed, ISU ABXIS, TiumBio, Be Biopharma, Regeneron Pharmaceuticals, Pfizer, Biocad, CSL Behring, Shanghai Vitalgen BioPharma, Baxalta, Amarna therapeutics, Catalyst Biosciences, Freeline Therapeutics, Belief BioMed, Centessa Pharmaceuticals, Novo Nordisk, Sanofi, Pfizer, and others

*
Key Acquired Hemophilia A Therapies: BBM-H901, ISU304, TU7710, BE-101, REGV131, PF-06838435, ANB-002, AAV5-hFIXco-Padua, VGB-R04, AskBio009, AMA005, CB 2679d-GT, FLT180a, BBM-H901, SerpinPC, Concizumab, Fitusiran , PF-06, and others

*
Acquired Hemophilia A Therapeutic Assessment: Acquired Hemophilia A current marketed and Acquired Hemophilia A emerging therapies

*
Acquired Hemophilia A Market Dynamics: Acquired Hemophilia A market drivers and Acquired Hemophilia A market barriers

Get a Free Sample PDF Report to know more about Acquired Hemophilia A Pipeline Assessment [https://www.delveinsight.com/sample-request/acquired-hemophilia-a-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1

Acquired Hemophilia A Report Introduction

2

Acquired Hemophilia A Executive Summary

3

Acquired Hemophilia A Overview

4

Acquired Hemophilia A- Analytical Perspective In-depth Commercial Assessment

5

Acquired Hemophilia A Pipeline Therapeutics

6

Acquired Hemophilia A Late Stage Products (Phase II/III)

7

Acquired Hemophilia A Mid Stage Products (Phase II)

8

Acquired Hemophilia A Early Stage Products (Phase I)

9

Acquired Hemophilia A Preclinical Stage Products

10

Acquired Hemophilia A Therapeutics Assessment

11

Acquired Hemophilia A Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Acquired Hemophilia A Key Companies

14

Acquired Hemophilia A Key Products

15

Acquired Hemophilia A Unmet Needs

16

Acquired Hemophilia A Market Drivers and Barriers

17

Acquired Hemophilia A Future Perspectives and Conclusion

18

Acquired Hemophilia A Analyst Views

19

Appendix

20

About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acquired-hemophilia-a-pipeline-2025-comprehensive-clinical-trials-and-therapies-analysis-with-key-moa-and-roa-insights-by-delveinsight-novo-nordisk-sanofi-pfizer-belief-biomed-centessa-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.